Madrigal Pharmaceuticals (MDGL) Publishes Rezdiffra Genetic Analysis, Is The Stock Cheap?

Madrigal Pharmaceuticals (MDGL) is back in focus after publishing a secondary MAESTRO NASH analysis in the Journal of Hepatology, showing Rezdiffra efficacy across common genetic risk variants in metabolic dysfunction associated steatohepatitis.

The latest journal publication lands after a choppy stretch for Madrigal Pharmaceuticals, with the share price down 14.8% over the past 30 days and 22.5% year to date, even as total shareholder return over five years is up almost 5x. This suggests long term momentum remains intact while near term sentiment reacts to shifting expectations around Rezdiffra and the broader MASH opportunity.

Scan beyond Madrigal Pharmaceuticals and look for other treatment-focused biotechs that could be approaching their own inflection points with the 20 high quality undiscovered gems.

Madrigal Pharmaceuticals now has a commercial product, rapid revenue growth and a fresh datapoint on Rezdiffra, yet the share price has slid sharply this year. Is that mix being valued fairly at about $460 a share, or not?

Most Popular Narrative: 32% Undervalued

Against a last close of $460.01, the most widely followed narrative pegs Madrigal Pharmaceuticals' fair value at $678.71, creating a wide gap that hinges on how durable Rezdiffra's opportunity really is.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

See why 14 investors see Madrigal Pharmaceuticals as 32% undervalued.

Result: Fair Value of $678.71 (UNDERVALUED)

Still, the Madrigal Pharmaceuticals story depends heavily on Rezdiffra, so any disappointing clinical data or slower than expected real world uptake could quickly pressure that undervalued narrative.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Next Steps

Curious whether this mix of risk and optimism around Madrigal Pharmaceuticals matches your own read of the situation? Move quickly, review the full risk and reward breakdown, and weigh those trade offs for yourself with the 3 key rewards and 1 important warning sign.

Looking for more Madrigal Pharmaceuticals style ideas?

Do not stop with Madrigal Pharmaceuticals. Use the Simply Wall St Screener to hunt for fresh opportunities that fit your own risk profile and return goals across the market.

• Target potential mispricing by scanning companies with strong fundamentals that still trade on modest expectations through the 32 high quality undervalued stocks.
• Prioritise resilience and financial strength by filtering for businesses that carry a solid buffer against shocks using the list of solid balance sheet and fundamentals (25 results).
• Seek out resilient performers with lower flagged risks and more predictable profiles by running a focused search via the 32 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com